- Home
- TRML
TRML
Tourmaline Bio Inc.
as 05-16-2025 4:00pm EST
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $49.33 | AVG Volume (30 days): | 315.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.56 - $29.79 | Next Earning Date: | 05-02-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 387.73% | Revenue Growth (next year): | N/A |
Latest Tourmaline Bio Inc. News
TRML Breaking Stock News: Dive into TRML Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
Simply Wall St.
a month ago
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation
GlobeNewswire
2 months ago
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
TipRanks
2 months ago
Robinhood initiated, MongoDB downgraded: Wall Street’s top analyst calls
GlobeNewswire
3 months ago
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
GlobeNewswire
4 months ago
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire
4 months ago
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
GlobeNewswire
5 months ago
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
Compare TRML vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRML Tourmaline Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.